EUVIMEDEUVIMED entdecken
Crossref

Liraglutide: a new option in the management of type 2 diabetes

Milan K Piya, Abd A Tahrani, Anthony H Barnett

Future Prescriber · 2008

DOI: 10.1002/fps.10 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Prescriber, 2008. Verfasst von Milan K Piya und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 diabetes mellitus (T2DM) is a global epidemic with an expected prevalence of 380 million in 2025 worldwide 1 and over 2.5 million by 2010 in the UK. 2 Diabetes is a progres‐sive disease which leads to macro and microvascular complications and reduced life expectancy. 2 Furthermore, diabetes‐related complications have been shown to worsen patients' quality of life. 3,4 Copyright © 2008 John Wiley & Sons, Ltd.

Zitieren

APA

Piya, M. K., Tahrani, A. A., & Barnett, A. H. (2008). Liraglutide: a new option in the management of type 2 diabetes. Future Prescriber. https://doi.org/10.1002/fps.10

Vancouver

Piya MK, Tahrani AA, Barnett AH. Liraglutide: a new option in the management of type 2 diabetes. Future Prescriber. 2008. doi:10.1002/fps.10

BibTeX
@article{Piya2008,
  author = {Piya, Milan K and Tahrani, Abd A and Barnett, Anthony H},
  title = {Liraglutide: a new option in the management of type 2 diabetes},
  journal = {Future Prescriber},
  year = {2008},
  doi = {10.1002/fps.10}
}
Kostenlos starten →